216 related articles for article (PubMed ID: 23382971)
21. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
22. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
23. Protein interacting with C kinase (PICK1) is a suppressor of spinocerebellar ataxia 3-associated neurodegeneration in Drosophila.
McGurk L; Bonini NM
Hum Mol Genet; 2012 Jan; 21(1):76-84. PubMed ID: 21949352
[TBL] [Abstract][Full Text] [Related]
24. FipoQ/FBXO33, a Cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein.
Chen ZS; Wong AKY; Cheng TC; Koon AC; Chan HYE
J Neurochem; 2019 Jun; 149(6):781-798. PubMed ID: 30685895
[TBL] [Abstract][Full Text] [Related]
25. Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3.
Johnson SL; Libohova K; Blount JR; Sujkowski AL; Prifti MV; Tsou WL; Todi SV
Neurobiol Dis; 2021 Dec; 160():105516. PubMed ID: 34563642
[TBL] [Abstract][Full Text] [Related]
26. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
27. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
28. Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila melanogaster.
Ristic G; Sutton JR; Libohova K; Todi SV
Neurobiol Dis; 2018 Aug; 116():78-92. PubMed ID: 29704548
[TBL] [Abstract][Full Text] [Related]
29. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila).
Kim YT; Shin SM; Lee WY; Kim GM; Jin DK
Cell Mol Neurobiol; 2004 Feb; 24(1):109-22. PubMed ID: 15049515
[TBL] [Abstract][Full Text] [Related]
30. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
31. Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM; Jardim LB
Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
[TBL] [Abstract][Full Text] [Related]
32. Spinocerebellar Ataxia Type 3 Pathophysiology-Implications for Translational Research and Clinical Studies.
Stahl F; Evert BO; Han X; Breuer P; Wüllner U
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612794
[TBL] [Abstract][Full Text] [Related]
33. Altered Levels of Proteins and Phosphoproteins, in the Absence of Early Causative Transcriptional Changes, Shape the Molecular Pathogenesis in the Brain of Young Presymptomatic Ki91 SCA3/MJD Mouse.
Wiatr K; Piasecki P; Marczak Ł; Wojciechowski P; Kurkowiak M; Płoski R; Rydzanicz M; Handschuh L; Jungverdorben J; Brüstle O; Figlerowicz M; Figiel M
Mol Neurobiol; 2019 Dec; 56(12):8168-8202. PubMed ID: 31201651
[TBL] [Abstract][Full Text] [Related]
34. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
35. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
Dantuma NP; Herzog LK
Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
[TBL] [Abstract][Full Text] [Related]
36.
Johnson SL; Prifti MV; Sujkowski A; Libohova K; Blount JR; Hong L; Tsou WL; Todi SV
Cells; 2022 Apr; 11(7):. PubMed ID: 35406787
[TBL] [Abstract][Full Text] [Related]
37. Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
J Neurol Sci; 2023 Nov; 454():120828. PubMed ID: 37865002
[TBL] [Abstract][Full Text] [Related]
38. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
39. Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.
Chakraborty A; Tapryal N; Venkova T; Mitra J; Vasquez V; Sarker AH; Duarte-Silva S; Huai W; Ashizawa T; Ghosh G; Maciel P; Sarkar PS; Hegde ML; Chen X; Hazra TK
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8154-8165. PubMed ID: 32205441
[TBL] [Abstract][Full Text] [Related]
40. [Inhibitory effect of VPA on multiple myeloma U266 cell proliferation and regulation of histone acetylation].
Zhu YF; Ye BG; Shen JZ; Lin CM; Lin FA; Shen SF; Xu CB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):638-41. PubMed ID: 20561418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]